Format

Send to

Choose Destination
J Med Chem. 2013 Aug 22;56(16):6297-313. doi: 10.1021/jm4001659. Epub 2013 May 15.

Development and therapeutic implications of selective histone deacetylase 6 inhibitors.

Author information

1
Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Illinois 60612, United States. jkalin1@jhmi.edu

Abstract

This Perspective provides an in depth look at the numerous disease states in which histone deacetylase 6 (HDAC6) has been implicated. The physiological pathways, protein-protein interactions, and non-histone substrates relating to different pathological conditions are discussed with regard to HDAC6. Furthermore, the compounds and methods used to modulate HDAC6 activity are profiled. The latter half of this Perspective analyzes reported HDAC6 selective inhibitors in terms of structure, potency, and selectivity over the other HDAC isoforms with the intent of providing a comprehensive overview of the molecular tools available. Potential obstacles and future directions of HDAC6 research are also presented.

PMID:
23627282
DOI:
10.1021/jm4001659
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center